Drug Misbranding Investigations Remain Top Priority: DOJ
A U.S. Department of Justice official told pharmaceutical companies and counsel on Tuesday that investigating drug misbranding will remain a major priority for the agency in the upcoming year, maintaining that...To view the full article, register now.
Already a subscriber? Click here to view full article